Turin, July 2021 – Corion Biotech S.r.l. signed an agreement with the University of Turin GMP Cell Factory which will support the company in the GMP production of CB-ChMF11, an innovative biological for the treatment of preeclampsia.

This is a pivotal milestone for the development of our placenta-derived “Cell Therapy Without Cells”.

The Officina Farmaceutica is located at the Molecular Biotechnology Center in Turin and represent the first Cell Factory in Piemonte to obtain the AIFA (Agenzia Italiana del Farmaco) authorization in July 2017. It is a national and international center of excellence for clinical trials and care of rare diseases thanks to the availability of innovative technologies.